Sign inCreate account

Report workspace tools

NCT05936138COMPLETEDanonymous

A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment

Sponsor

Source record

Eli Lilly and Company

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

LY3502970

Indication / condition

AI-normalized

Renal Insufficiency

Intervention

Source record

LY3502970

Source & freshness

Source record

NCT ID

NCT05936138

Original source

ClinicalTrials.gov

Source last updated

Apr 23, 2024

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05936138

Title

A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment

Sponsor

Eli Lilly and Company

Status

COMPLETED

Phase

PHASE1

Condition raw

Renal Insufficiency

Condition normalized

Renal Insufficiency

Modality raw

orforglipron

Modality normalized

small molecule

Target raw

LY3502970

Target normalized

LY3502970

Interventions

LY3502970

Public preview

Source record

A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment is a PHASE1 clinical asset sponsored by Eli Lilly and Company in Renal Insufficiency, Healthy. SEO and diligence focus: LY3502970, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05936138

Status

COMPLETED

Phase

PHASE1

Sponsor

Eli Lilly and Company

Executive brief

Investment-Ready Snapshot

A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment is a PHASE1 clinical asset sponsored by Eli Lilly and Company in Renal Insufficiency, Healthy. SEO and diligence focus: LY3502970, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 23, 2024
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05936138

Indication

Renal Insufficiency

Modality

small molecule

Target

LY3502970

Intervention

LY3502970

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.